Clovis Oncology (NASDAQ:CLVS)

CAPS Rating: 2 out of 5

Recs

0
Player Avatar TMFBiologyFool (97.11) Submitted: 9/18/2013 7:00:29 PM : Underperform Start Price: $74.20 CLVS Score: +62.02

Pipeline doesn't justify $2.2 billion valuation.

Member Avatar Hope4GoodFuture (< 20) Submitted: 9/30/2013 4:08:09 PM
Recs: 0

agree. And experience observing pancreatic cancer trial ("LEAP", low hENT, high hENT debacle) makes me skeptical of anything this management says.

Featured Broker Partners


Advertisement